<DOC>
	<DOCNO>NCT02523430</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy HepaSphere interventional therapy use digital subtraction angiography（DSA） nasopharyngeal carcinoma .</brief_summary>
	<brief_title>HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>By enrol patient nasopharyngeal carcinoma adapt enrolled criterion , study document first time safety short long term efficacy HepaSphere interventional therapy use digital subtraction angiography （DSA） nasopharyngeal carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>1 . Age:1880 2 . Karnofsky performance status &gt; 60 3 . Diagnosis nasopharyngeal carcinoma base histology current accept radiological measure . 4 . Classification tumor , node , metastasisclassification ( TNM ) stage : Ⅱ , Ⅲ , Ⅳ 5 . Will receive interventional therapy 6 . Life expectancy : Greater 3 month 7 . Patients ' routine blood test , liver function kidney function obvious abnormality 8 . Ability understand study protocol willingness sign write informed consent document 1 . Patients primary tumor except nasopharyngeal carcinoma 2 . History coagulation disorder anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Nasopharyngeal Carcinoma</keyword>
	<keyword>HepaSphere</keyword>
</DOC>